Agreement regarding the labelling of Risk Communication Material

Agreement regarding the labelling of risk communications and educational material for healthcare professionals

The Icelandic Medicines Agency (IMA) and the Icelandic Association of the Pharmaceutical Industry (Frumtök) have in cooperation designed a symbol which is intended to help healthcare professionals (HCPs) distinguish between important risk communications/educational material sent in agreement with IMA and  other material sent by marketing authorisation holders (MAHs), e.g. promotional material.  

IMA and the Icelandic Association of the Pharmaceutical Industry (Frumtök) signed an agreement regarding the use of this symbol on 29 November 2012.

All MAHs are invited and encouraged to apply for the use of this symbol by becoming part of the aforementioned agreement. In order to be allowed to use the symbol, an e-mail has to be submitted to IMA (ima@ima.is), where the MAH requests to be part of the agreement and thereby accepting its conditions, i.e. to use it and use it only for risk communication sent to the relevant HCPs in agreement with IMA, following the agency‘s assessment, i.e.:

 

  • Educative material published for centralised products to fulfill CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT in Annex II, C/D of their marketing authorisation,
  • Educative material published for medicinal products following a referral, in accordance with a Commission Decision,
  • Educative material published in agreement with IMA, due to commitments in a RMP approved by the rapporteur/RMS/NA,
  • Risk communication sent due to requirements of EMA/IMA and in agreement with IMA, after IMA´s assessment, e.g. Direct Healthcare Professional Communication letters (DHPCs).

 

It is strictly forbidden to use the symbol in context with promotional material.

The symbol should be used to label envelopes (on a sticker/label or printed on the envelope itself, in colour). The location on the envelope is not specified but it should be clearly visible. The IMA also recommends the use of the symbol on Direct Healthcare Professional Communication (DHPC) letters, e.g. in the header of the first page. This also applies to any annexes to specific safety information and educational material.

Notwithstanding this additional field of application the label shall always be used on envelopes, whether the contained documents are identified in the same manner or not.

The symbol can only be used for material which is distributed upon request or by special permission of the agency.

MAHs who have joined the agreement are:

Abbott
Abbvie
Accord 
Actavis
Actelion Registration
Alcon
ALK-Abelló
Allergan Norden
Allergan Pharmaceuticals International Ltd. 
Allergen Pharmaceuticals Ireland 
Alvetra GmbH
Alvogen IPCo S.à.r.l. 
Amgen
Arthropharm Europe Limited
Astellas
AstraZeneca
Baxter
Bayer
Bayer Animal Health GmbH
BGP Products AB 
BGP Products Aps 
BGP Products Ltd 
Biogen Idec
Bioglan Pharma AB
BMS
Boeringer Ingelheim
CCS
Celgene
Celltrion 
Ceva Sante Animale
Chanelle UK Limited
Cheplapharm Arzneimittel
Chiesi Farmaceutici SpA 
Clintec Parenteral SA
Colgate Palmolive A/S
CSL Behring AB
Daiichi Sankyo Europe GmbH
Dentsply De Trey
Desitin Arzneimittel
Dopharma Research B.V.
Eisai
Elan Pharma International Ltd.
Elanco Animal Health A/S
Eli Lilly
Expanscience
Ferring
Fresenius Kabi
Fresenius Medical Care
Galderma
GE Healthcare
Gedeon Richter Nordics AB 
Generics Ltd UK 
Genzyme Europe B.V. 
Gilead
Grünenthal GmbH
GSK
Hospira
Intendis GmbH Berlin
Intercept 
Janssen Biologics B.V. 
Janssen-Cilag
Kela Laboratories NV
Kyowakirin 
LEO Pharma
Les Laboratories Servier
Linde Healthcare - ÍSAGA 
Lohmann Animal Health
Lundbeck
LYFIS
Martindale Pharmaceuticals
The Medicines Company UK Limited
MEDA
medac Gesellschaft für klinische Spezialpräparate GmbH 
Medical
Medice Arzneimittel Pütter GmbH & Co. KG 
Medilink
Medimpex UK Limited
Mentholatum Company Ltd.
Merck
MercuryPharma
MSD
Mylan AB 
Mylan Hospital AS 
Myla SAS 
Norbrook
Nordic Drugs
Norpharma A/S
Novartis
Novo Nordisk
Octapharma Nordic
Orifarm Generics A/S
Orion Corporation
Otsuka 
Pfizer
Pfizer Oy Animal Health
PharmaCoDane
Pharmacosmos A/S
Pharma Nord ApS
Pierre Fabré
Raptor Pharmaceuticals Europe B.V. 
Reckitt Benckiser Healthcare
Roche
Sandoz GmbH
Sanofi
Sanofi-Pasteur MSD
Santen Oy
Shire Pharmaceuticals Ltd.
SkyePharma PLC
Smith & Nephew
STADA Arzneimittel AG
Swedish Orphan Biovitrum (Sobi) 
Takeda
TEVA
Thea
Tillotts Pharma AB
UCB
United Therapeutics Europe Ltd. 
Vétoquinol
Vian S.A.
Vifor Pharma
Williams & Halls ehf.